Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK discusses the pooled analysis of NCT01236391, NCT01599949 and NCT01646021 trials which all analysed at the outcome of mantle cell lymphoma (MCL) patients treated with ibrutinib. Overall, there were 370 patients with a complete remission (CR) of 20% and an overall response rate (ORR) of 66%. In patients who achieved CR over 90% were still alive after 2 years. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
The success of ibrutinib in treating mantle cell lymphoma (MCL)
